Imagine this: while catching breast cancer early can mean a survival rate over 99%, that number plummets to just over 30% once it has spread, a stark gap that defines the modern story of cancer survival where stage, subtype, and access to care shape your odds as powerfully as the diagnosis itself.
Key Takeaways
- The 5-year relative survival rate for localized breast cancer in the United States (2014-2020 data) is 99.3%.
- The 5-year relative survival rate for regional breast cancer in women under 50 in the US is 86.5%.
- For distant metastatic breast cancer, the 5-year survival rate among US females is 31.9% (SEER 2014-2020).
- The 5-year relative survival rate for localized prostate cancer in the US (2014-2020) is 100%.
- Regional prostate cancer 5-year survival rate is 100% per SEER data (2014-2020).
- Distant stage prostate cancer has a 5-year survival of 34.5% in the US.
- The 5-year survival rate for localized non-small cell lung cancer (NSCLC) is 65% (US 2014-2020).
- Regional NSCLC 5-year survival is 37% per SEER data.
- Distant metastatic NSCLC has 9% 5-year survival in the US.
- The 5-year relative survival for localized colorectal cancer is 90.4% (US 2014-2020).
- Regional colorectal cancer 5-year survival rate is 72.3% per SEER.
- Distant stage colorectal cancer has 16.6% 5-year survival in the US.
- The 5-year survival for localized pancreatic cancer is 44.3% (US 2014-2020).
- Regional pancreatic cancer 5-year survival is 16.2% per SEER data.
- Distant pancreatic adenocarcinoma has 3.4% 5-year survival.
Cancer survival rates vary widely by type, stage, location, and treatment.
Breast Cancer
1The 5-year relative survival rate for localized breast cancer in the United States (2014-2020 data) is 99.3%.
Verified2The 5-year relative survival rate for regional breast cancer in women under 50 in the US is 86.5%.
Verified3For distant metastatic breast cancer, the 5-year survival rate among US females is 31.9% (SEER 2014-2020).
Verified4In the UK, the 10-year net survival rate for breast cancer diagnosed in 2010-2011 is 78% for females.
Directional5Age-standardized 5-year survival for breast cancer in Australia (2014-2018) is 90.8%.
Single source6For HER2-positive breast cancer with targeted therapy, 5-year survival exceeds 90% in early stages (US data).
Verified7Black women in the US have a 5-year breast cancer survival rate of 81.6% compared to 91.4% for white women (2014-2020).
Verified8In Japan, 5-year survival for stage 0 breast cancer is nearly 100% (2006-2008 data).
Verified9European age-standardized 5-year survival for breast cancer (2000-2007) averaged 81.6%.
Directional10For triple-negative breast cancer, 5-year survival is 77% for localized disease (US).
Single source11Overall US cancer 5-year relative survival (2014-2020) improved to 68.7%.
Verified12From 1975-2020, US cancer 5-year survival rose from 49% to 68%.
Verified13Pediatric cancer 5-year survival in US now exceeds 85% (2015-2020).
Verified14Women with stage 0 breast cancer have 5-year survival of 100% (US SEER).
Directional15Inflammatory breast cancer 5-year survival is 41% (US data).
Single source16Male breast cancer 5-year survival is 89.9% overall (US 2014-2020).
Verified17In Canada, breast cancer 5-year net survival is 89.6% (2014-2018).
Verified18BRCA1 mutation carriers have 5-year survival of 88% for breast cancer.
Verified19Post-mastectomy radiotherapy boosts 10-year survival by 5% in node-positive cases.
Directional20Endocrine therapy improves 15-year survival by 3.8% in ER-positive breast cancer.
Single source21Ductal carcinoma in situ breast cancer 5-year survival 98.9% (US SEER).
Verified22Lobular breast cancer 5-year survival 90.2% vs 91.5% ductal.
Verified23Neoadjuvant chemotherapy response: 5-year survival 92% pathologic complete response.
Verified24In India, breast cancer 5-year survival 66.1% urban areas (2018).
Directional25DCIS treated with lumpectomy + radiation: 10-year survival 98%.
Single source26Paget's disease of nipple 5-year survival 85-90% (US data).
Verified27Younger women (<40) breast cancer 5-year survival 84% (US).
Verified2820-year survival for early breast cancer 78.4% with tamoxifen (EBCTCG).
VerifiedBreast Cancer Interpretation
While these numbers showcase remarkable progress against cancer, they also serve as a stark reminder that our survival too often depends on a brutal lottery of geography, genetics, stage, subtype, and the persistent shadow of health inequities.
Colorectal Cancer
1The 5-year relative survival for localized colorectal cancer is 90.4% (US 2014-2020).
Verified2Regional colorectal cancer 5-year survival rate is 72.3% per SEER.
Verified3Distant stage colorectal cancer has 16.6% 5-year survival in the US.
Verified4UK 10-year net survival for colon cancer (2010-2011) is 59%.
Directional5Rectal cancer 5-year survival in Australia (2014-2018) is 68.5%.
Single source6Screening-detected colorectal cancer has 5-year survival over 90% (US).
Verified7Black patients with colorectal cancer have 5-year survival of 62.3% vs 66.1% whites.
Verified8In Europe, 5-year survival for colorectal cancer (2000-2007) is 56.3%.
Verified9MSI-high colorectal tumors have 5-year survival of 75% vs 60% for MSS.
Directional10Colon cancer localized 5-year survival 92.2%, regional 71.5% (recent US).
Single source11Right-sided colon cancer 5-year survival 64% vs 72% left-sided.
Verified12KRAS wild-type colorectal cancer with EGFR inhibitors: survival benefit 4 months.
Verified13In Germany, colorectal cancer 5-year survival 66% (2019).
Verified14MSI-high metastatic colorectal cancer immunotherapy: 5-year survival 33%.
Directional15Total mesorectal excision rectal cancer 5-year survival 75% locally advanced.
Single source16Stage II colorectal cancer 5-year survival 82.3% (US).
Verified17Adjuvant FOLFOX stage III colon cancer 5-year DFS 72%.
Verified18Liver metastases resection colorectal cancer 5-year survival 58%.
Verified19In UK, bowel cancer 5-year survival improved to 59% (2016-2020).
Directional20Cetuximab + chemo KRAS wt mCRC median survival 28 months.
Single source21Watch-and-wait rectal cancer 5-year local regrowth-free 78%.
VerifiedColorectal Cancer Interpretation
The cold, hard truth of these numbers is that catching colorectal cancer early is an almost assured victory, while letting it slip into the shadows turns the fight into a brutal, and often losing, battle of inches.
Lung Cancer
1The 5-year survival rate for localized non-small cell lung cancer (NSCLC) is 65% (US 2014-2020).
Verified2Regional NSCLC 5-year survival is 37% per SEER data.
Verified3Distant metastatic NSCLC has 9% 5-year survival in the US.
Verified4Small cell lung cancer (SCLC) limited stage 5-year survival is 30%.
Directional5UK 10-year net survival for lung cancer (2010-2011) is 14%.
Single source6Australian 5-year survival for lung cancer (2014-2018) is 23.2%.
Verified7Smokers with lung cancer have 5-year survival of 18% vs 24% for never-smokers (US).
Verified8In Japan, 5-year survival for stage I lung cancer is 82.1% (2015 data).
Verified9Women with NSCLC have 5-year survival of 28% vs 23% for men (US).
Directional10Targeted therapy for EGFR-mutant NSCLC boosts 5-year survival to 40% in advanced stages.
Single source11Stage IA NSCLC 5-year survival is 90% (US SEER 2014-2020).
Verified12Stereotactic body radiotherapy for early-stage NSCLC: 5-year survival 71%.
Verified13ALK-positive NSCLC with inhibitors: 5-year survival 60% advanced disease.
Verified14In France, lung cancer 5-year survival 18% (2018 data).
Directional15Never-smokers lung cancer 5-year survival 28.8% (US).
Single source16Immunotherapy (pembrolizumab) median survival 30 months in PD-L1 high NSCLC.
Verified17SCLC extensive stage 5-year survival 3% (US SEER).
Verified18Stage IIIB NSCLC 5-year survival 17% (US SEER).
Verified19ROS1 fusion NSCLC crizotinib median PFS 19 months.
Directional20Combined chemo-immunotherapy NSCLC OS 17.1 months median.
Single source21In Brazil, lung cancer 5-year survival 16.5% (2018).
Verified22Adenocarcinoma lung cancer 5-year survival 28% vs 19% squamous (US).
Verified23Prophylactic cranial irradiation SCLC survival benefit 5% at 3 years.
VerifiedLung Cancer Interpretation
These statistics paint a stark, stage-by-stage map of lung cancer survival where the battleground is won or lost in the early margins, yet even in advanced disease, a few precise keys—like targeted therapies—can unlock doors once thought firmly shut.
Pancreatic Cancer
1The 5-year survival for localized pancreatic cancer is 44.3% (US 2014-2020).
Verified2Regional pancreatic cancer 5-year survival is 16.2% per SEER data.
Verified3Distant pancreatic adenocarcinoma has 3.4% 5-year survival.
Verified4UK 1-year net survival for pancreatic cancer (2016-2020) is 25.7%.
Directional5Australian 5-year survival for pancreatic cancer (2014-2018) is 11.4%.
Single source6Resectable pancreatic cancer post-surgery has 5-year survival of 28%.
Verified7Black patients with pancreatic cancer have 5-year survival of 9.6% vs 11.8% whites.
Verified8In Japan, 5-year survival for stage I pancreatic cancer is 50.2% (2015).
Verified9Neoadjuvant therapy improves pancreatic cancer 5-year survival to 38% for borderline resectable.
Directional10FOLFIRINOX neoadjuvant improves pancreatic cancer R0 resection to 70%.
Single source11Stage I pancreatic cancer 5-year survival 42% post-resection (US).
Verified12Gemcitabine + nab-paclitaxel median survival 8.5 months metastatic pancreatic.
Verified13In Italy, pancreatic cancer 5-year survival 10.9% (EUROCARE).
Verified14BRCA2-mutant pancreatic cancer PARP inhibitor olaparib: survival benefit 7 months.
Directional15Adjuvant mFOLFIRINOX 5-year survival 53.5% resected pancreatic cancer.
Single source16Head of pancreas tumors 5-year survival 10% vs 5% body/tail.
Verified17Pancreatic neuroendocrine tumors grade 1 5-year survival 97%.
Verified18FOLFIRINOX metastatic pancreatic median OS 11.1 months.
Verified19Stage IIA pancreatic cancer 5-year survival 39.1%.
Directional20In Australia, pancreatic cancer 3-year survival 18.3% (recent).
Single source21Neoadjuvant therapy borderline resectable pancreatic 5-year survival 47%.
Verified22Gemcitabine monotherapy metastatic pancreatic median survival 5.7 months.
VerifiedPancreatic Cancer Interpretation
The statistics for pancreatic cancer survival are a stark reminder that our best medical achievements, from early detection in Japan to aggressive chemotherapy regimens like FOLFIRINOX, are still desperately fighting an uphill battle against a disease that remains far too lethal.
Prostate Cancer
1The 5-year relative survival rate for localized prostate cancer in the US (2014-2020) is 100%.
Verified2Regional prostate cancer 5-year survival rate is 100% per SEER data (2014-2020).
Verified3Distant stage prostate cancer has a 5-year survival of 34.5% in the US.
Verified4In the UK, 10-year net survival for prostate cancer (2010-2011) is 78%.
Directional5Australian 5-year survival for prostate cancer (2014-2018) is 95.1%.
Single source6Men over 75 with localized prostate cancer have 5-year survival of 99.8% (US).
Verified7Black men in the US have a 5-year prostate cancer survival rate of 96.8% vs 99.1% for whites.
Verified8In Canada, 5-year net survival for prostate cancer (2014-2018) is 94.3%.
Verified9European 5-year survival for prostate cancer (2000-2007) is 87.9% age-standardized.
Directional10Gleason score 6 prostate cancer has 10-year survival near 99% with treatment.
Single source11Gleason 8-10 prostate cancer 5-year survival is 95.7% localized (US).
Verified12Active surveillance for low-risk prostate cancer yields 97% 10-year survival.
Verified13Radiation therapy for intermediate-risk prostate cancer: 5-year survival 99%.
Verified14In Sweden, prostate cancer 10-year relative survival is 87% (2017 data).
Directional15PSMA-targeted therapy improves survival in metastatic prostate cancer to 18 months median.
Single source16Hispanic men prostate cancer 5-year survival 96.5% (US SEER).
Verified17Robot-assisted prostatectomy 5-year biochemical recurrence-free survival 90%.
Verified18ADT plus docetaxel extends survival in high-risk prostate cancer by 17 months.
Verified19Low-risk prostate cancer 15-year prostate cancer-specific survival 94%.
Directional20High-risk prostate cancer with brachytherapy: 10-year survival 76%.
Single source21Metastatic castration-resistant prostate cancer enzalutamide median survival 32 months.
Verified22In China, prostate cancer 5-year survival 93% (2020 registry).
Verified23Hypofractionated radiation 5-year survival 98% low-risk prostate.
Verified24Salvage prostatectomy 5-year biochemical control 60% post-radiation failure.
DirectionalProstate Cancer Interpretation
This data declares, with almost cheeky optimism, that the secret to surviving prostate cancer is catching it before it throws a going-away party for your other organs.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CANCERcancer.orgVisit source
- Reference 3CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 4AIHWaihw.gov.auVisit source
- Reference 5CANCERcancer.govVisit source
- Reference 6GANJOHOganjoho.jpVisit source
- Reference 7EUROCAREeurocare.nextproject.orgVisit source
- Reference 8BREASTCANCERbreastcancer.orgVisit source
- Reference 9CANCERcancer.caVisit source
- Reference 10LUNGCANCERRESEARCHFOUNDATIONlungcancerresearchfoundation.orgVisit source
- Reference 11PROGRESSREPORTprogressreport.cancer.govVisit source
- Reference 12BCRFbcrf.orgVisit source
- Reference 13NEJMnejm.orgVisit source
- Reference 14THELANCETthelancet.comVisit source
- Reference 15AUANETauanet.orgVisit source
- Reference 16SOCIALSTYRELSENsocialstyrelsen.seVisit source
- Reference 17JAMANETWORKjamanetwork.comVisit source
- Reference 18NCBIncbi.nlm.nih.govVisit source
- Reference 19INVSinvs.santepubliquefrance.frVisit source
- Reference 20KREBSDATENkrebsdaten.deVisit source
- Reference 21REDJOURNALredjournal.orgVisit source
- Reference 22CICAMScicams.ac.cnVisit source
- Reference 23INCAinca.gov.brVisit source
- Reference 24ANNALSOFONCOLOGYannalsofoncology.orgVisit source